Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

D. Demetri, George; De Braud, Filippo; Drilon, Alexander; Siena, Salvatore; R. Patel, Manish; Chul Cho, Byoung; V. Liu, Stephen; Ahn, Myung-Ju; Chiu, Chao-Hua; J. Lin, Jessica; Goto, Koichi; Lee, Jeeyun; Bazhenova, Lyudmila; John, Thomas; Fakih, Marwan; P. Chawla, Sant; Dziadziuszko, Rafal; Seto, Takashi; Heinzmann, Sebastian; Pitcher, Bethany; Chen, David; R. Wilson, Timothy; Rolfo, Christian

doi:10.1158/1078-0432.ccr-21-3597

Public

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

Published in Clinical Cancer Research • Feb 10, 2022

Authors:

George D. Demetri

Filippo De Braud

Alexander Drilon

Abstract

PURPOSE: Entrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and previously induced deep [objective response rate (ORR) 57.4%] and durable [median duration of response (DoR) 10.4 months] responses in adults with NTRK fusion-positive solid tumors from three phase I/II tri...

Subject

Medicine

Oncology

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!